{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Adams RA"],"funding":["Cancer Research UK","Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["3693-3704"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8601309"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(33)"],"pubmed_abstract":["Purpose
Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in patients who are responding to first-line therapy.Methods
FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed mCRC. The FOCUS4-N trial was offered to patients in whom a targeted subtrial was unavailable or biomarker tests failed. Patients were randomly assigned using a 1:1 ratio between maintenance capecitabine and active monitoring (AM). The primary outcome was progression-free survival (PFS) with secondary o"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial."],"pmcid":["PMC8601309"],"funding_grant_id":["25350","MC_UU_12023/20","G0701770","NIHR200162","11/100/50","MC_UU_00004/01","MC_UU_12023/25","MC_UU_00004/02"],"pubmed_authors":["Maughan TS","Kaplan R","Shiu KK","Quirke P","Brown E","FOCUS4 Trial Investigators","Richman SD","Middleton G","Graham J","Butler R","Falk S","Wilson RH","Seligmann JF","Samuel L","Fisher DJ","Seymour M","Wasan H","Parmar M","Collinson F","Brown LC","Adams RA","Yates E"],"additional_accession":[]},"is_claimable":false,"name":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.","description":"Purpose
Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in patients who are responding to first-line therapy.Methods
FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed mCRC. The FOCUS4-N trial was offered to patients in whom a targeted subtrial was unavailable or biomarker tests failed. Patients were randomly assigned using a 1:1 ratio between maintenance capecitabine and active monitoring (AM). The primary outcome was progression-free survival (PFS) with secondary o","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-04T23:36:49.67Z","creation":"2024-10-19T06:51:09.011Z"},"accession":"S-EPMC8601309","cross_references":{"pubmed":["34516759"],"doi":["10.1200/JCO.21.01436"]}}